ITGB2 and pancreatic neoplasm: Canertinib treatment resulted in marginal decrease of pFAK in MiaPaCa-1 cells, whereas complete inhibition of pFAK was achieved in MUC4 positive pancreatic cancer cells (CD18/HPAF and Capan-1) (Fig. 4A).